Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation

  1. Xin Zhou
  2. Jennifer W Li
  3. Zirong Chen
  4. Wei Ni
  5. Xuehui Li
  6. Rongqiang Yang
  7. Huangxuan Shen
  8. Jian Liu
  9. Franco J DeMayo
  10. Jianrong Lu
  11. Frederic J Kaye
  12. Lizi Wu  Is a corresponding author
  1. University of Florida, United States
  2. Sun Yat-sen University, China
  3. Zhejiang University, China
  4. NIH, United States
  5. University of Florida College of Medicine, United States

Abstract

Lung cancer with loss-of-function of the LKB1 tumor suppressor is a common aggressive subgroup with no effective therapies. LKB1-deficiency induces constitutive activation of cAMP/CREB-mediated transcription by a family of three CREB-regulated transcription coactivators (CRTC1-3). However, the significance and mechanism of CRTC activation in promoting the aggressive phenotype of LKB1-null cancer remain poorly characterized. Here we observed overlapping CRTC expression patterns and mild growth phenotypes of individual CRTC-knockouts in lung cancer, suggesting functional redundancy of CRTC1-3. We consequently designed a dominant-negative mutant (dnCRTC) to block all three CRTCs to bind and co-activate CREB. Expression of dnCRTC efficiently inhibited the aberrantly activated cAMP/CREB-mediated oncogenic transcriptional program induced by LKB1-deficiency, and specifically blocked the growth of human and murine LKB1-inactivated lung cancer. Collectively, this study provides direct proof for an essential role of the CRTC-CREB activation in promoting the malignant phenotypes of LKB1-null lung cancer and proposes the CRTC-CREB interaction interface as a novel therapeutic target.

Data availability

The transcriptomic data were deposited in the NCBI GEO database GSE157722.All data generated or analyzed for this study are included in the manuscript.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Xin Zhou

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Jennifer W Li

    Department of Medicine, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Zirong Chen

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Wei Ni

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Xuehui Li

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Rongqiang Yang

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Huangxuan Shen

    Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Jian Liu

    ZJU-UoE Institute, Zhejiang University, Haining, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Franco J DeMayo

    NIH, Research Triangle Park, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Jianrong Lu

    Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4969-6040
  11. Frederic J Kaye

    Medicine, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Lizi Wu

    Molecular Genetics & Microbiology, University of Florida, Gainesville, United States
    For correspondence
    lzwu@ufl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0076-2617

Funding

National Cancer Institute (R01CA234351)

  • Lizi Wu

National Institute of Dental and Craniofacial Research (R01DE023641)

  • Lizi Wu

UF Health Cancer Center

  • Lizi Wu

National Institute of Environmental Health Sciences (Z1AES103311-01)

  • Franco J DeMayo

University of Florida Gatorade Trust

  • Frederic J Kaye

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies were performed following a protocol approved by the IACUC (Institutional Animal Care & Use Committee) of the University of Florida (201810386). All animals were housed, cared for, and used in an animal care facility at the University of Florida that is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) program in compliance with the Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act and other applicable state and local regulations.

Reviewing Editor

  1. Erica A Golemis, Fox Chase Cancer Center, United States

Version history

  1. Received: December 29, 2020
  2. Accepted: June 17, 2021
  3. Accepted Manuscript published: June 18, 2021 (version 1)
  4. Version of Record published: June 28, 2021 (version 2)
  5. Version of Record updated: July 2, 2021 (version 3)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,256
    Page views
  • 290
    Downloads
  • 4
    Citations

Article citation count generated by polling the highest count across the following sources: PubMed Central, Crossref, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xin Zhou
  2. Jennifer W Li
  3. Zirong Chen
  4. Wei Ni
  5. Xuehui Li
  6. Rongqiang Yang
  7. Huangxuan Shen
  8. Jian Liu
  9. Franco J DeMayo
  10. Jianrong Lu
  11. Frederic J Kaye
  12. Lizi Wu
(2021)
Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation
eLife 10:e66095.
https://doi.org/10.7554/eLife.66095

Further reading

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Xiaoquan Zhu, Chao Chen ... Yanyang Zhao
    Research Article Updated

    Identification oncogenes is fundamental to revealing the molecular basis of cancer. Here, we found that FOXP2 is overexpressed in human prostate cancer cells and prostate tumors, but its expression is absent in normal prostate epithelial cells and low in benign prostatic hyperplasia. FOXP2 is a FOX transcription factor family member and tightly associated with vocal development. To date, little is known regarding the link of FOXP2 to prostate cancer. We observed that high FOXP2 expression and frequent amplification are significantly associated with high Gleason score. Ectopic expression of FOXP2 induces malignant transformation of mouse NIH3T3 fibroblasts and human prostate epithelial cell RWPE-1. Conversely, FOXP2 knockdown suppresses the proliferation of prostate cancer cells. Transgenic overexpression of FOXP2 in the mouse prostate causes prostatic intraepithelial neoplasia. Overexpression of FOXP2 aberrantly activates oncogenic MET signaling and inhibition of MET signaling effectively reverts the FOXP2-induced oncogenic phenotype. CUT&Tag assay identified FOXP2-binding sites located in MET and its associated gene HGF. Additionally, the novel recurrent FOXP2-CPED1 fusion identified in prostate tumors results in high expression of truncated FOXP2, which exhibit a similar capacity for malignant transformation. Together, our data indicate that FOXP2 is involved in tumorigenicity of prostate.

    1. Cancer Biology
    2. Genetics and Genomics
    Ann-Kathrin Herzfeldt, Marta Puig Gamez ... Lee Kim Swee
    Research Article

    Cytotoxic CD8+ T lymphocytes (CTLs) are key players of adaptive anti-tumor immunity based on their ability to specifically recognize and destroy tumor cells. Many cancer immunotherapies rely on unleashing CTL function. However, tumors can evade killing through strategies which are not yet fully elucidated. To provide deeper insight into tumor evasion mechanisms in an antigen-dependent manner, we established a human co-culture system composed of tumor and primary immune cells. Using this system, we systematically investigated intrinsic regulators of tumor resistance by conducting a complementary CRISPR screen approach. By harnessing CRISPR activation (CRISPRa) and CRISPR knockout (KO) technology in parallel, we investigated gene gain-of-function as well as loss-of-function across genes with annotated function in a colon carcinoma cell line. CRISPRa and CRISPR KO screens uncovered 187 and 704 hits respectively, with 60 gene hits overlapping between both. These data confirmed the role of interferon‑γ (IFN-γ), tumor necrosis factor α (TNF-α) and autophagy pathways and uncovered novel genes implicated in tumor resistance to killing. Notably, we discovered that ILKAP encoding the integrin-linked kinase-associated serine/threonine phosphatase 2C, a gene previously unknown to play a role in antigen specific CTL-mediated killing, mediate tumor resistance independently from regulating antigen presentation, IFN-γ or TNF-α responsiveness. Moreover, our work describes the contrasting role of soluble and membrane-bound ICAM-1 in regulating tumor cell killing. The deficiency of membrane-bound ICAM-1 (mICAM-1) or the overexpression of soluble ICAM-1 (sICAM-1) induced resistance to CTL killing, whereas PD-L1 overexpression had no impact. These results highlight the essential role of ICAM-1 at the immunological synapse between tumor and CTL and the antagonist function of sICAM-1.